|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2000-2-10
|
|
pubmed:abstractText |
Protease inhibitors are efficient drugs as part of highly active antiretroviral therapy. They have been shown to cause hyper- and dyslipoproteinemia. Since antiretroviral therapy is able to delay disease progression and possibly extend life expectancy in HIV-infected individuals, the precise nature of serum lipid disturbances may become of clinical interest with respect to its atherogenicity and to finding treatment options.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0954-6820
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
246
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
567-75
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10620100-Adult,
pubmed-meshheading:10620100-CD4 Lymphocyte Count,
pubmed-meshheading:10620100-HIV Protease Inhibitors,
pubmed-meshheading:10620100-HIV Seropositivity,
pubmed-meshheading:10620100-Humans,
pubmed-meshheading:10620100-Indinavir,
pubmed-meshheading:10620100-Lipoproteins,
pubmed-meshheading:10620100-Male,
pubmed-meshheading:10620100-Middle Aged,
pubmed-meshheading:10620100-Nelfinavir,
pubmed-meshheading:10620100-Prospective Studies,
pubmed-meshheading:10620100-Ritonavir,
pubmed-meshheading:10620100-Viral Load
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Influence of protease inhibitor therapy on lipoprotein metabolism.
|
|
pubmed:affiliation |
Department of Internal Medicine I, University of Bonn, Germany. berthold@uni-bonn.de
|
|
pubmed:publicationType |
Journal Article
|
